High BRE expression is an independent prognostic factor for OS and EFS, based on the multivariate Cox regression hazard model
| . | OS . | EFS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| High BRE expression based on mean of all AML + 4× SD (12 patient samples) | ||||||
| High BRE | 0.15 | 0.042-0.52 | .003 | 0.13 | 0.038-0.47 | .002 |
| MLL-AF9 | 1.82 | 0.81-4.1 | .15§ | 1.52 | 0.68-3.4 | .31§ |
| Favorable karyotype* | 0.30 | 0.21-0.43 | < .001 | 0.32 | 0.23-0.44 | < .001 |
| CEBPA double mut | 0.26 | 0.14-0.50 | < .001 | 0.28 | 0.16-0.50 | < .001 |
| NPM1 mut | 0.45 | 0.34-0.59 | < .001 | 0.41 | 0.31-0.53 | < .001 |
| FLT3 ITD | 1.60 | 1.2-2.1 | < .001 | 1.55 | 1.2-2.0 | .001 |
| Transplantation status† | 0.68 | 0.60-0.78 | < .001 | 0.75 | 0.66-0.85 | < .001 |
| FAB M5 | 1.05 | 0.80-1.4 | .73 | 1.00 | 0.77-1.3 | .98 |
| Age, y‡ | 1.01 | 1.0-1.0 | .080 | 1.00 | 1.0-1.0 | .52 |
| WBC‡ | 1.00 | 1.0-1.0 | .097 | 1.00 | 1.0-1.0 | .027 |
| High BRE expression based on mean of all AML + 3× SD (14 patient samples) | ||||||
| High BRE | 0.30 | 0.094-0.98 | .047 | 0.26 | 0.08-0.83 | .023 |
| MLL-AF9 | 1.29 | 0.52-3.22 | .58§ | 1.11 | 0.46-2.7 | .82§ |
| Favorable karyotype* | 0.31 | 0.22-0.45 | < .001 | 0.33 | 0.24-0.46 | < .001 |
| CEBPA double mut | 0.28 | 0.15-0.52 | < .001 | 0.30 | 0.17-0.52 | < .001 |
| NPM1 mut | 0.47 | 0.36-0.62 | < .001 | 0.43 | 0.33-0.56 | < .001 |
| FLT3 ITD | 1.54 | 1.2-2.0 | .001 | 1.48 | 1.1-1.9 | .003 |
| Transplantation status† | 0.70 | 0.61-0.80 | < .001 | 0.76 | 0.67-0.87 | < .001 |
| FAB M5 | 1.09 | 0.83-1.4 | .54 | 1.05 | 0.81-1.4 | .72 |
| Age, y‡ | 1.01 | 1.0-1.0 | .059 | 1.00 | 1.0-1.0 | .43 |
| WBC‡ | 1.00 | 1.0-1.0 | .32 | 1.00 | 1.0-1.0 | .13 |
| . | OS . | EFS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| High BRE expression based on mean of all AML + 4× SD (12 patient samples) | ||||||
| High BRE | 0.15 | 0.042-0.52 | .003 | 0.13 | 0.038-0.47 | .002 |
| MLL-AF9 | 1.82 | 0.81-4.1 | .15§ | 1.52 | 0.68-3.4 | .31§ |
| Favorable karyotype* | 0.30 | 0.21-0.43 | < .001 | 0.32 | 0.23-0.44 | < .001 |
| CEBPA double mut | 0.26 | 0.14-0.50 | < .001 | 0.28 | 0.16-0.50 | < .001 |
| NPM1 mut | 0.45 | 0.34-0.59 | < .001 | 0.41 | 0.31-0.53 | < .001 |
| FLT3 ITD | 1.60 | 1.2-2.1 | < .001 | 1.55 | 1.2-2.0 | .001 |
| Transplantation status† | 0.68 | 0.60-0.78 | < .001 | 0.75 | 0.66-0.85 | < .001 |
| FAB M5 | 1.05 | 0.80-1.4 | .73 | 1.00 | 0.77-1.3 | .98 |
| Age, y‡ | 1.01 | 1.0-1.0 | .080 | 1.00 | 1.0-1.0 | .52 |
| WBC‡ | 1.00 | 1.0-1.0 | .097 | 1.00 | 1.0-1.0 | .027 |
| High BRE expression based on mean of all AML + 3× SD (14 patient samples) | ||||||
| High BRE | 0.30 | 0.094-0.98 | .047 | 0.26 | 0.08-0.83 | .023 |
| MLL-AF9 | 1.29 | 0.52-3.22 | .58§ | 1.11 | 0.46-2.7 | .82§ |
| Favorable karyotype* | 0.31 | 0.22-0.45 | < .001 | 0.33 | 0.24-0.46 | < .001 |
| CEBPA double mut | 0.28 | 0.15-0.52 | < .001 | 0.30 | 0.17-0.52 | < .001 |
| NPM1 mut | 0.47 | 0.36-0.62 | < .001 | 0.43 | 0.33-0.56 | < .001 |
| FLT3 ITD | 1.54 | 1.2-2.0 | .001 | 1.48 | 1.1-1.9 | .003 |
| Transplantation status† | 0.70 | 0.61-0.80 | < .001 | 0.76 | 0.67-0.87 | < .001 |
| FAB M5 | 1.09 | 0.83-1.4 | .54 | 1.05 | 0.81-1.4 | .72 |
| Age, y‡ | 1.01 | 1.0-1.0 | .059 | 1.00 | 1.0-1.0 | .43 |
| WBC‡ | 1.00 | 1.0-1.0 | .32 | 1.00 | 1.0-1.0 | .13 |
Mut indicates mutation; FAB, French-American-British; WBC, white blood cell count; OS, overall survival; EFS, event-free survival; HR, hazard ratio; and CI, confidence interval.
Favorable karyotype: t(8;21), t(15;17), and inv(16).
Transplantation status: either no transplantation, autologous transplantation, or allogeneic transplantation.
Continuous variables.
The P value of MLL-AF9 is mainly affected by co-occurrence with high BRE expression (based on correlation of regression coefficients, data not shown).